Vaccinex Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Vaccinex, Inc. (VCNX)
Company Research
Source: GlobeNewswire
Patients are currently being screened and enrolled in two studies of pepinemab as monotherapy in Alzheimer’s disease and in combination with KEYTRUDA® in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Ended the second quarter with cash and cash equivalents of $22.4 million ROCHESTER, N.Y., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced financial results for the second quarter ended June 30, 2021 and provided a corporate update. “During the second quarter and subsequent period, we achieved significant milestones by initiating clinical trials in both Alzheimer’s disease (AD) and metastatic head and neck cancer (HNSCC). We believe that successfully advancing these programs will demonstrate the versatility of pepinemab’s mechanism of action in serious diseases in which SEMA4D overexpr
Show less
Read more
Impact Snapshot
Event Time:
VCNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VCNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VCNX alerts
High impacting Vaccinex, Inc. news events
Weekly update
A roundup of the hottest topics
VCNX
News
- Vaccinex Reports 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Vaccinex Reports 2023 Financial Results and Provides Corporate UpdateGlobeNewswire
- Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules [Yahoo! Finance]Yahoo! Finance
- Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesGlobeNewswire
- Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology [Yahoo! Finance]Yahoo! Finance
VCNX
Sec Filings
- 5/9/24 - Form 424B3
- 5/9/24 - Form 8-K
- 5/8/24 - Form S-3/A
- VCNX's page on the SEC website